Ingenol mebutate: all 56 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic KeratosisCompletedNCT03200912Phase 3Results posted
• Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant RecipientsCompletedNCT02866695Phase 4Results posted
• Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic KeratosisCompletedNCT02716714Phase 4Results posted
• A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic KeratosisCompletedNCT02654769Phase 3Results posted
• To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic KeratosisCompletedNCT02459795Phase 3Results posted
• To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic KeratosisCompletedNCT02385318Phase 3Results posted
• Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or ChestCompletedNCT02361216Phase 3Results posted
• Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic KeratosesCompletedNCT02251652Phase 4Results posted
• Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic KeratosisCompletedNCT01998984Phase 2Results posted
• Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%CompletedNCT01926496Phase 4Results posted
• Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic KeratosisCompletedNCT01820260Phase 1/2Results posted
• A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/ExtremitiesCompletedNCT01787383Phase 3Results posted
• Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and ScalpCompletedNCT01600014Phase 3Results posted
• PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal MicroscopyCompletedNCT01449513Phase 1Results posted
• A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head LocationsCompletedNCT00942604Phase 3Results posted
• A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)CompletedNCT00916006Phase 3Results posted
• A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)CompletedNCT00915551Phase 3Results posted
• A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic KeratosisCompletedNCT00852137Phase 2Results posted
• A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head LocationsCompletedNCT00742391Phase 3Results posted
• A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)CompletedNCT00700063Phase 2Results posted
• Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell CarcinomaCompletedNCT03546166Phase 2
• Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged SkinCompletedNCT03508856Not applicable
• Evaluation of Ingenol Mebutate for Actinic Cheilitis TreatmentWithdrawnNCT03452566Phase 1/2
• Picato for the Treatment of Molluscum Contagiosum in Immunocompromised PatientsWithdrawnNCT03336372Early Phase 1
• Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs CryotherapyCompletedNCT02990221Phase 4
• Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.CompletedNCT02748902Phase 1
• Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the FaceCompletedNCT02723721Phase 2
• Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or ScalpCompletedNCT02406014Phase 4
• Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital WartsCompletedNCT02377999Phase 2
• IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic KeratosisStatus unknownNCT02281682Phase 4
• Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic KeratosisCompletedNCT02242747Not applicable
• Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use ConditionsCompletedNCT02124239Phase 1
• Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%CompletedNCT01892137Phase 1
• Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and ScalpCompletedNCT01836367Phase 1
• Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the ForearmCompletedNCT01803477Phase 1/2
• Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin LesionsWithdrawnNCT01735942Early Phase 1
• PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by HistologyCompletedNCT01387711Phase 1
• PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy SubjectsCompletedNCT01302925Phase 1
• Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged SkinCompletedNCT01214577Phase 2
• Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic KeratosisCompletedNCT01214564Phase 2
• A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)CompletedNCT00917306Phase 3
• A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy VolunteersCompletedNCT00850811Phase 1
• A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy VolunteersCompletedNCT00850681Phase 1
• Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2CompletedNCT00659893Phase 1
• The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)WithdrawnNCT00546611Phase 1
• A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the HandCompletedNCT00544297Phase 2
• Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005CompletedNCT00544258Phase 1
• To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCCCompletedNCT00432185Phase 2
• A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical GelCompletedNCT00427050Phase 2
• Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic KeratosesCompletedNCT00375739Phase 2
• Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test DesignCompletedNCT00357916Phase 1
• Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In SituCompletedNCT00329121Phase 2
• Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical GelCompletedNCT00239135Phase 2
• Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell CarcinomaCompletedNCT00108134Phase 2
• Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell CarcinomaCompletedNCT00108121Phase 2
• Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic KeratosesCompletedNCT00107965Phase 2

← Ingenol mebutate overview